Two products from Shandong Linuo Pharmaceutical, a wholly-owned subsidiary of Keyuan Pharmaceutical, have entered the proposed selection list for the 12th National Drug Procurement. The company's stock closed up 5.04% on the day. Among them, the 4 mg and 8 mg specifications of betahistine hydrochloride tablets have completed the approval for the change of marketing authorization holder, while isavuconazonium sulfate for injection was proposed for selection directly under the subsidiary's name. Due to the change in the holder entity, the proposed selection entity for betahistine hydrochloride tablets will subsequently be replaced. The company noted that it is currently only in the proposed selection public notice stage, with the procurement cycle running until December 31, 2029, and there is uncertainty regarding the final revenue contribution of the products. As of the close of the day, Keyuan Pharmaceutical's stock price was 35.45 yuan, up 5.04%, with a total market capitalization of 3.839 billion yuan.
Shandong Keyuan Pharmaceutical Co. Ltd. ATwo products entered the proposed selection list for national drug procurement, potentially boosting sales.